Raised $0 · Aug 11, 2026announcement ↗
AquaNab
Backed by
BiotechHamburg, Germanyaquanabs.de ↗
What they do
AquaNab develops feed-administered nanoantibody therapies for preventing and treating diseases in farmed fish. Its initial product focus is non-toxic, residue-free treatment for sea lice and other pathogens affecting salmon farming, serving aquaculture producers.
Hiring outlook
Because the funding round and company stage are undisclosed, likely near-term needs are research and development roles in biologics, aquaculture, and formulation, along with regulatory and pilot-trial support. Commercial hiring may follow as products advance toward validation and market approval.
Open roles
No open roles on their board right now.